Comparison of QEEG Indicator in Children with ADHA in Two Group Receiving Automoxetin and Ritalin

Abstract

Attention Deficit Hyperactivity Disorder is one of the most common neurobehavioral disorders in childhood and affects a large proportion of the world's population, characterized by general characteristics of inattention, lack of concentration, and impulsivity. The prevalence of this disorder in school children is 5-8% and 85-60% of these children will have symptoms in adolescence. In boys it is 2-9 times more than girls. The treatment for this disorder is medication and psychotherapy interventions. Various treatment plans have been proposed, including drug therapy and non-drug methods. They have used QEEG technology as a diagnostic aid tool to assess the response to treatment of people with ADHD and other learning and attention problems. The aim of this study was to compare QEEG indices in children with ADHD in the two groups receiving Atomoxetine and Ritalin. Materials and methods: The study is an interventional (clinical trial) and the statistical population includes children with ADHD. 75 male children with ADHD aged 7-12 years were included in the study based on DSM5 criteria and KSAD test and based on the diagnosis of psychiatric subspecialty based on inclusion criteria. Patients were randomly divided into two groups of treatment with Ritalin and Atomoxetine. Samples were evaluated at the beginning of the study and 3 months after the start of drug treatment with Connors parental questionnaires to determine the severity of symptoms. Also, QEEG was performed to evaluate the patients' response to drug therapy at the beginning and 3 months after the start of treatment to evaluate the changes in brain wave indices. Data were analyzed using SPSS 19 and P-Value <0.05. Results: In this study, the most changes occurred before and after receiving Ritalin in the absolute power of alpha 2 and delta bands and the relative power of alpha 2 and beta 3. Atomoxetine also had a significant effect on reducing the beta band.